Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients [article]

Guillermo Rosa-Diez, Maria M Papaginovic-Leiva, Fernando Lombi, Maria S Crucelegui, Ricardo D Martinez, Hernan Trimarchi, Ruben Schiavelli, Mercedes Grizzo, Miguel Rano, Ricardo M . Heguilen, Rocio A Jones, Luciana Gonzalez-Paganti (+7 others)
2021 medRxiv   pre-print
Given the vulnerability of people with chronic kidney disease to COVID-19, nephrology societies have issued statements calling for prioritization of these patients for vaccination. It is not yet known whether COVID-19 vaccines confer the same high level of protection in patients with kidney disease. The aims of this study were to evaluate the safety measured by the events supposedly attributed to vaccines and the effectiveness evaluated by the presence of antibodies in dialysis patients
more » ... d with the COVID-19 Sputnik V vaccine. Methods: multicenter, observational, and analytical study of a prospective cohort of hemodialysis patients in the Autonomous City of Buenos Aires with a vaccination plan. Patients older than 18 years on dialysis who received both components of the COVID-19 vaccine were included. Results: 491 patients included in the safety analysis. ESAVI with either the first or second component was detected in 186 (37.9% 95% CI 33.6%-42.34%). The effectiveness analysis measures of antibodies against SARS-Cov-2 were performed in 102 patients, 98% had positive IgG against SARS-Cov-2 antibodies 21 days after the second component. In patients with COVID-19 prior to vaccination, antibodies at day 21 after the first component reached almost the highest levels compared to those patients who did not have COVID-19, and the rise between the last measures was lower than patients without COVID-19. Conclusion: Dialysis patients constitute a vulnerable population for SARS-Cov-2 infection, beyond the recommendations that were implemented by dialysis units, full vaccination is a priority and necessary. The Sputnik V vaccine has been shown to be safe and effective in this patient population.
doi:10.1101/2021.10.21.21265349 fatcat:n5gqn5qpznhttckgey2c3wmjyq